BackgroundThe development of rapidly progressive interstitial lung disease (RP-ILD) in patients with anti-MDA5-positive dermatomyositis-associated interstitial lung disease (MDA5+ DM-ILD) is a major cause of adverse outcomes, including mortality. This study aimed to identify factors influencing the occurrence of RP-ILD in patients with MDA5+ DM-ILD.MethodsA systematic search was conducted in PubMed, EMBASE, the Cochrane Library, Web of Science, and Scopus for studies investigating factors associated with RP-ILD in MDA5+ DM-ILD, with the search period extending to January 1, 2026.
The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Meta-analysis was performed using Stata 18.0 software.ResultsFifteen studies were included in the meta-analysis, all of which were of high quality, with an average NOS score of 7.9.
Frontiers in Immunology published a clinical update in Infectious Disease on 10 Apr 2026.
The item focuses on Influencing factors for rapidly progressive interstitial lung disease in patients with anti-MDA5 antibody-positive dermatomyositis: a systematic review and meta-analysis.
Review the original article for the full source wording and details.